Ligand Pharmaceuticals LGND Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's total current liabilities?
- Ligand Pharmaceuticals (LGND) reported total current liabilities of $40.67M in Q1 2026.
- How has Ligand Pharmaceuticals's total current liabilities changed year-over-year?
- Ligand Pharmaceuticals's total current liabilities decreased by 30.7% year-over-year, from $58.68M to $40.67M.
- What is the long-term trend for Ligand Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total current liabilities has grown at a -17.9% compound annual growth rate (CAGR), from $100.11M to $37.45M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.